These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 25015210)

  • 1. Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor.
    Mésange P; Poindessous V; Sabbah M; Escargueil AE; de Gramont A; Larsen AK
    Oncotarget; 2014 Jul; 5(13):4709-21. PubMed ID: 25015210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops.
    Adamcic U; Skowronski K; Peters C; Morrison J; Coomber BL
    Neoplasia; 2012 Jul; 14(7):612-23. PubMed ID: 22904678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies.
    Poindessous V; Ouaret D; El Ouadrani K; Battistella A; Mégalophonos VF; Kamsu-Kom N; Petitprez A; Escargueil AE; Boudou P; Dumont S; Cervera P; Fléjou JF; André T; Tournigand C; Chibaudel B; de Gramont A; Larsen AK
    Clin Cancer Res; 2011 Oct; 17(20):6522-30. PubMed ID: 21880790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
    Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
    Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
    Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
    Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tanshinone IIA inhibits β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in normoxic and HIF-1α in hypoxic microenvironments in human colorectal cancer.
    Sui H; Zhao J; Zhou L; Wen H; Deng W; Li C; Ji Q; Liu X; Feng Y; Chai N; Zhang Q; Cai J; Li Q
    Cancer Lett; 2017 Sep; 403():86-97. PubMed ID: 28602978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of VEGF induces cellular senescence in colorectal cancer cells.
    Hasan MR; Ho SH; Owen DA; Tai IT
    Int J Cancer; 2011 Nov; 129(9):2115-23. PubMed ID: 21618508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation.
    Brossa A; Grange C; Mancuso L; Annaratone L; Satolli MA; Mazzone M; Camussi G; Bussolati B
    Oncotarget; 2015 May; 6(13):11295-309. PubMed ID: 25948774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.
    Piao Y; Liang J; Holmes L; Zurita AJ; Henry V; Heymach JV; de Groot JF
    Neuro Oncol; 2012 Nov; 14(11):1379-92. PubMed ID: 22965162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-148a inhibits early relapsed colorectal cancers and the secretion of VEGF by indirectly targeting HIF-1α under non-hypoxia/hypoxia conditions.
    Tsai HL; Miao ZF; Chen YT; Huang CW; Yeh YS; Yang IP; Wang JY
    J Cell Mol Med; 2019 May; 23(5):3572-3582. PubMed ID: 30834693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer.
    Schiffmann LM; Fritsch M; Gebauer F; Günther SD; Stair NR; Seeger JM; Thangarajah F; Dieplinger G; Bludau M; Alakus H; Göbel H; Quaas A; Zander T; Hilberg F; Bruns CJ; Kashkar H; Coutelle O
    Br J Cancer; 2019 Jan; 120(1):69-78. PubMed ID: 30377339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab terminates homeobox B9-induced tumor proliferation by silencing microenvironmental communication.
    Hoshino Y; Hayashida T; Hirata A; Takahashi H; Chiba N; Ohmura M; Wakui M; Jinno H; Hasegawa H; Maheswaran S; Suematsu M; Kitagawa Y
    Mol Cancer; 2014 May; 13():102. PubMed ID: 24885802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms.
    Wagner J; Kline CL; Zhou L; Khazak V; El-Deiry WS
    J Exp Clin Cancer Res; 2018 Jan; 37(1):11. PubMed ID: 29357916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors.
    Nilsson MB; Zage PE; Zeng L; Xu L; Cascone T; Wu HK; Saigal B; Zweidler-McKay PA; Heymach JV
    Oncogene; 2010 May; 29(20):2938-49. PubMed ID: 20208561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
    Ding C; Li L; Yang T; Fan X; Wu G
    BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.
    Iwai T; Sugimoto M; Harada S; Yorozu K; Kurasawa M; Yamamoto K
    Oncol Rep; 2016 Aug; 36(2):626-32. PubMed ID: 27350037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time-dependent stabilization of hypoxia inducible factor-1α by different intracellular sources of reactive oxygen species.
    Calvani M; Comito G; Giannoni E; Chiarugi P
    PLoS One; 2012; 7(10):e38388. PubMed ID: 23144690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.
    Rapisarda A; Hollingshead M; Uranchimeg B; Bonomi CA; Borgel SD; Carter JP; Gehrs B; Raffeld M; Kinders RJ; Parchment R; Anver MR; Shoemaker RH; Melillo G
    Mol Cancer Ther; 2009 Jul; 8(7):1867-77. PubMed ID: 19584228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
    Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
    World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.